Biocept Inc., (a San Diego-based commercial-stage cancer
diagnostics company providing liquid biopsy tests for doctors and their
patients with cancer) has quite recently won a new patent in Australia. The
granted patent provides Intellectual
Property (IP)
Protection to Biocept's
Primer-Switch technology that is efficient and useful in performing ctDNA
(circulating tumor DNA) analysis with the help of real-time PCR and associated
analysis methods, such as next-generation sequencing (NGS).
The chief scientific officer at Biocept, Lyle Arnold, stated that
the grant of the new patent expands the company's robust IP protection for rare
mutation detection. He further said that the Primer-Switch is a method capable
of detecting the rare genetic events, and is an addition to Biocept's
Switch-Blocker technology, which is used in a routine with the company's ctDNA
Target Selector assays.
Arnold mentioned that it is indeed the first patent issued for
Biocept's Primer-Switch technology, which the company believes would end up
achieving worldwide Patent
Protection. He also added that the granted patent is now another tool in
Biocept's toolkit of methods, which shall inform on biomarkers to help
physician decision-making in the treatment of cancer patients. Moreover, the
company explained that the Australian patent describes another exclusive method
for particularly enriching patient specimens for oncogene mutations of
interest.
The Primer-Switch technology is proactively used as a critical
part of PCR reactions, which are integral to the most commonly-used method of
amplification in diagnostic assays. The Primer-Switch methodology holds immense
potential for finding diverse use in PCR reactions, specifically, in scenarios
where there is a need to detect rare genetic events or have way more precise
PCR amplification.
Michael Nall, the CEO at Biocept Inc, stated that the expansion of
Biocept's IP would continue to be the global validation of its technology,
which, in turn, would position the company as a provider of cutting-edge
approaches to detect rare genetic events with the help of blood and other
fluids. He also said that Biocept would keep coming up with innovative
technologies and products like Primer-Switch to stay ahead of the curve in
liquid biopsy technology. For more visit: https://www.kashishipr.com/
Don’t forget to follow us on social
media:
Contact
- US
No comments:
Post a Comment